Peptides vs supplements vs medications — the budget allocation question

Here is an attempt at one.

Start with the cost of doing nothing about lifestyle. This is not rhetorical. Exercise, sleep, nutrition, and stress management are the interventions with the most robust and consistent evidence across almost every health outcome studied. They are also largely free — they require time and attention but not a supplement budget. A person who sleeps seven to nine hours in reasonable architecture, exercises regularly with both resistance and cardiovascular components, eats in a way that supports protein adequacy and vegetable variety, and manages chronic psychological stress is operating from a biological foundation that no supplement stack or peptide protocol can replicate. This is the starting point for the allocation question, not a preamble to it. The question "where should I spend my health dollars?" has a different answer for someone who has addressed the lifestyle fundamentals than for someone who hasn't.

Assuming the lifestyle baseline is genuinely in place, the next layer is foundational supplementation for documented or probable deficiencies. This is inexpensive. Vitamin D deficiency is extraordinarily common in populations that spend most of the day indoors and at northern latitudes; supplementing it costs five to fifteen dollars a month and has a well-characterized evidence base for bone health, immune function, and probably other outcomes. Magnesium is similarly common in deficiency, inexpensive to supplement, and relevant to hundreds of enzymatic reactions, sleep regulation, and cardiovascular function. Omega-3 fatty acids from fish oil have a large and reasonably robust evidence base for cardiovascular risk, inflammation, and potentially cognitive outcomes; quality matters more than price, but a solid product costs twenty to forty dollars monthly. These three items, in the right doses for your actual deficiency status, represent perhaps forty to fifty dollars a month and address some of the most commonly inadequate nutrients in modern diets. The evidence-per-dollar ratio here is as good as it gets anywhere in the health optimization space.

The next tier is functional supplementation — compounds with evidence for specific applications in people without documented deficiency but with plausible physiological benefit. Creatine monohydrate has one of the most consistent and well-replicated evidence bases in sports nutrition and is now being studied more broadly for cognitive outcomes and aging applications; it costs fifteen to twenty-five dollars a month at standard doses. NAC has strong evidence in specific clinical applications and reasonable evidence for glutathione support more broadly; inexpensive. Melatonin at low doses (0.5 to 1 mg) has evidence for circadian regulation and sleep onset, particularly when timing is an issue; inexpensive. Protein supplementation, if dietary protein is genuinely inadequate for lean mass maintenance and activity level, is essentially a food cost. This tier might run another twenty to fifty dollars a month and covers a meaningful set of well-studied targets. None of these require a prescription, all of them have a reasonable evidence base for specific applications, and all of them are accessible.

Now you are perhaps at one hundred dollars a month for the foundational plus functional supplement tier, and you've addressed the interventions with the most consistent evidence for most people.

Prescription medications belong in a separate category because their cost and evidence structure are different. Statins, ACE inhibitors, metformin, thyroid hormone replacement, antidepressants, antihypertensives — these are medications with substantial evidence bases, FDA approval for specific indications, and established clinical frameworks for prescribing, monitoring, and adjusting. For someone with a documented indication, these medications are typically covered at least partially by insurance and available as generics for very low out-of-pocket cost — often five to thirty dollars a month. The evidence quality for these medications, in their specific indications, is generally higher than for most supplements or peptides: they've been through the clinical trial infrastructure, the mechanisms are well-characterized, and the prescribing and monitoring protocols are established. If you have a condition that a proven generic medication addresses, the cost-per-evidence-unit is extraordinarily favorable. Optimizing that layer of care — making sure documented conditions are appropriately managed with evidence-based medications — is foundational before allocating significant resources elsewhere.

Compounded peptides represent a meaningful step up in cost and a meaningful change in evidence quality — though the direction of that change is complicated. A well-chosen peptide protocol from a reputable compounding pharmacy, with prescribing provider oversight and appropriate lab monitoring, might run one hundred to three hundred dollars a month for a single compound, or two hundred to a thousand dollars a month for a more comprehensive protocol. This is a substantial budget commitment. The evidence for compounded peptides varies dramatically by compound: Tesamorelin has rigorous FDA-approved clinical trial data. Sermorelin has decades of research and a reasonable evidence base for its mechanism. BPC-157 has a large preclinical literature but limited rigorous human trials. Ipamorelin and CJC-1295 have pharmacological characterization and clinical use but a smaller published evidence base than you'd expect given their widespread use. The category is not uniform, and the evidence quality within it ranges from well-established to primarily mechanistic and animal-based.

What peptides can potentially offer that supplements can't is mechanism-specificity at a physiological level — receptor-mediated signaling that affects biology in targeted ways that a vitamin or a botanical can't replicate. What supplements sometimes offer that peptides don't is a longer and more rigorous evidence base in human populations, simpler administration, and substantially lower cost. These are not equivalent categories competing for the same job, which is part of why the allocation question is worth thinking through carefully rather than defaulting to either camp.

The longevity clinic or concierge medicine model adds another layer of cost on top of the medication and peptide costs: membership fees, consultation fees, comprehensive testing panels, and program overhead that can run five hundred to two thousand dollars a month or more before any interventions are purchased. What this model provides — when it's done well — is integration: a clinical team that oversees all the interventions together, interprets labs in context, adjusts protocols based on response, and coordinates across the various axes being addressed. The value of that integration is real for people whose health picture is genuinely complex and who benefit from active clinical management. The cost of it may not be justified for someone with a simpler picture who could achieve similar results through a primary care relationship with a physician who is conversant in this space.

The allocation framework, assembled honestly, looks something like this. Address lifestyle fundamentals first — these are your most powerful interventions and they are essentially free. Cover documented deficiencies and foundational supplementation — this is fifty to one hundred dollars a month and has the best evidence-per-dollar profile. Ensure appropriate evidence-based prescription medications for any documented conditions are prescribed and monitored — often low-cost or insurance-covered. From there, if there are specific goals that the foundational layer doesn't address — a recovery or sleep picture that hasn't improved with lifestyle optimization, body composition goals that foundational work has plateaued on, hormonal changes that lab values and symptoms suggest would benefit from specific intervention — then targeted peptide protocols, with prescribing provider oversight and specific monitoring, may have a place in the allocation.

The opportunity cost framing is worth sitting with directly. Three hundred dollars a month on peptide protocols is thirty-six hundred dollars a year. Over a decade, that's thirty-six thousand dollars. Over the course of a health span, the cumulative cost of a sustained optimization protocol is a significant financial commitment. Whether that commitment is worthwhile depends on what it's actually accomplishing — and that depends on whether the specific interventions are well-chosen, whether the goals are achievable through those mechanisms, and whether the lifestyle and foundational layers are genuinely in place. An expensive peptide protocol that sits on top of inadequate sleep and poor nutritional habits is an expensive substitution for the cheaper and more effective thing.

None of this means peptides aren't worth the cost for the right person in the right context. What it means is that the decision deserves the same rational scrutiny you'd apply to any significant budget allocation. What specific outcome are you pursuing? Is there evidence that this intervention supports that outcome? Have you addressed the more evidence-dense and cost-effective interventions in that area first? Are you working with a prescribing provider who can help you evaluate whether the intervention is working, and adjust if it isn't? Those questions — asked clearly, answered honestly — produce better health outcomes than any particular category of intervention. Your prescribing provider is the right partner for that conversation, not because the compliance matters for its own sake, but because the integration of your specific clinical picture with the evidence landscape for the interventions you're considering is genuinely complex enough to benefit from clinical expertise. The budget question is a health question. Answer it like one.